Compare · DNA vs GILD
DNA vs GILD
Side-by-side comparison of Ginkgo Bioworks Holdings Inc. (DNA) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DNA and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $195.13B, about 257.9x DNA ($756.6M).
- GILD has been more active in the news (5 items in the past 4 weeks vs 4 for DNA).
- GILD has more recent analyst coverage (25 ratings vs 18 for DNA).
- Company
- Ginkgo Bioworks Holdings Inc.
- Gilead Sciences Inc.
- Price
- -
- -
- Market cap
- $756.6M
- $195.13B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- 1992
- News (4w)
- 4
- 5
- Recent ratings
- 18
- 25
Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings, Inc. develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is based in Boston, Massachusetts.
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest DNA
- Ginkgo Bioworks to Provide Autonomous Lab Access to NSF X-Labs Researchers, Contributing Cloud Lab Time and Protein Testing Services to $1.5 Billion Breakthrough Science Program
- Araceli Biosciences and Ginkgo Bioworks Bring Cellular Imaging at Scale to Nebula's Lab-in-the-Loop
- SEC Form 4 filed by Ginkgo Bioworks Holdings Inc.
- Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium
- Director Henry Christian O sold $35,405 worth of shares (5,000 units at $7.08), decreasing direct ownership by 21% to 19,310 units (SEC Form 4)
- Ginkgo Datapoints Announces Partnership with TuneLab to Close the Gap between AI Models and Lab Data
- SEC Form 144 filed by Ginkgo Bioworks Holdings Inc.
- Ginkgo Bioworks Joins ARPA-H GIVE Program to Build Autonomous Manufacturing System for Individualized RNA Medicines
- Officer Coen Steven P. converted options into 743 shares and sold $2,302 worth of shares (330 units at $6.98), increasing direct ownership by 0.80% to 51,851 units (SEC Form 4) (tax liability)
- Ginkgo Bioworks downgraded by TD Cowen with a new price target
Latest GILD
- SEC Form 4 filed by Gilead Sciences Inc.
- SEC Form 4 filed by Gilead Sciences Inc.
- SEC Form 144 filed by Gilead Sciences Inc.
- Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
- Chairman & CEO O'Day Daniel Patrick sold $2,218,508 worth of shares (15,000 units at $147.90) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 566,683 units (SEC Form 4)
- SVP, Controllership Burkhart Erin converted options into 2,223 shares and covered exercise/tax liability with 768 shares (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $435,870 worth of shares (3,000 units at $145.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 164,096 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $432,646 worth of shares (3,000 units at $144.22) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 116,684 units (SEC Form 4)
- A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
- Chief Financial Officer Dickinson Andrew D converted options into 2,797 shares and covered exercise/tax liability with 1,347 shares, increasing direct ownership by 0.88% to 167,096 units (SEC Form 4)